English

ONCOGENEX PHARMACEUTICALS, INC.

EDGAR

ACHV Quarterly report (10-Q) · filed 2026-08-11

151 filing records in this dataset, filed from 1996-08-13 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

0 USD

2019 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-15.2 million USD

2019 · USD

Exact inputs and evidence

Operating Cash Flow: -15216000 USD Source

Free cash flow

-15.3 million USD

2019 · USD

Exact inputs and evidence

Operating Cash Flow: -15216000 USD Source
Capital Expenditure: 53000 USD Source

Cash and cash equivalents: 48 million USD 2026-06-30 Source
Exact value

47958000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 103 million shares 2026-06-30 Source
Exact value

102717200 shares

Reported share-count change

106.74% · 53 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

49685072 shares · 2025-06-30· Source
102717200 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-114 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -14441000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -54648000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -40000000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -10168000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -74769000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2019-12-31
operating income: No compatible figures in this window
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 14.82 million

Prior period

−USD 39.83 million

2024-01-01 – 2024-12-31
Current period

−USD 54.65 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-54648000 − -39827000 = -14821000 USD

-39827000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-54648000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Year-over-year change in Net income: -14821000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -54648000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#3534379 Filing: 000119312526120690 Input fundies:NetIncome: -39827000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#3536102 Filing: 000119312526120690
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 19.73 million

Prior period

−USD 29.77 million

2024-01-01 – 2024-12-31
Current period

−USD 49.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-49500000 − -29770000 = -19730000 USD

-29770000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-49500000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Year-over-year change in Operating cash flow: -19730000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -49500000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#2013479 Filing: 000119312526120690 Input fundies:OperatingCashFlow: -29770000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1875301 Filing: 000119312526120690
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 0
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 16.4 million

Cash

Operating cash flow −USD 15.22 million
Capital expenditure USD 53,000
Free cash flow Derived −USD 15.27 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	0	Unavailable	Unavailable	Unavailable	-12687000	-10669000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -12687000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -10623000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 46000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	0	Unavailable	Unavailable	Unavailable	-16395000	-15269000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -16395000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -15216000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 53000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Operating margin	Not reported	Revenue: 0 Open source
2019-12-31	Operating margin	Not reported	Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -12687000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -16395000 Open source Revenue: 0 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -10623000 Open source Capital Expenditure: 46000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -15216000 Open source Capital Expenditure: 53000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -15.2M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-10623000	Operating Cash Flow: -10623000 Open source
20192019-12-31	Operating cash flow	-15216000	Operating Cash Flow: -15216000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -15.3M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-10669000	Operating Cash Flow: -10623000 Open source Capital Expenditure: 46000 Open source
20192019-12-31	Free cash flow	-15269000	Operating Cash Flow: -15216000 Open source Capital Expenditure: 53000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

14.4% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	17.2%	Total Liabilities: 3282000 Open source Total Assets: 19084000 Open source
20192019-12-31	Liabilities / assets	14.4%	Total Liabilities: 3028000 Open source Total Assets: 21078000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.04× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	4.75×	Current Assets: 15537000 Open source Current Liabilities: 3270000 Open source
20192019-12-31	Current assets / current liabilities	6.04×	Current Assets: 17334000 Open source Current Liabilities: 2869000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 1.23 million Exact value Exact value: -1234000 USD 2016-01-01 – 2016-12-31: -1234000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2016-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -1234000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1234000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459019007838/achv-20181231.xml#236199 Filing: 000156459019007838 The citation records this snapshot. The page link may show a newer release later.	−USD 202,000 Exact value Exact value: -202000 USD 2016-01-01 – 2016-12-31: -202000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2016-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -202000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -202000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459019007838/achv-20181231.xml#265440 Filing: 000156459019007838 The citation records this snapshot. The page link may show a newer release later.	USD 46,000 Exact value Exact value: 46000 USD 2016-01-01 – 2016-12-31: 46000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2016-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 46000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 46000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459017002109/ogxi-20161231.xml#228656 Filing: 000156459017002109 The citation records this snapshot. The page link may show a newer release later.	−USD 248,000 Calculation and evidence -202000 − 46000 USD Exact free cash flow: -248000 USD 2016-01-01 – 2016-12-31: -202000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 46000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2016-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -248000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -202000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459019007838/achv-20181231.xml#265440 Filing: 000156459019007838 Input fundies:CapitalExpenditure: 46000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459017002109/ogxi-20161231.xml#228656 Filing: 000156459017002109 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 10.58 million Exact value Exact value: -10583000 USD 2017-01-01 – 2017-12-31: -10583000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2017-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -10583000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10583000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459020010642/achv-20191231.xml#296052 Filing: 000156459020010642 The citation records this snapshot. The page link may show a newer release later.	−USD 9.11 million Exact value Exact value: -9107000 USD 2017-01-01 – 2017-12-31: -9107000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2017-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -9107000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9107000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459020010642/achv-20191231.xml#336216 Filing: 000156459020010642 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 12.69 million Exact value Exact value: -12687000 USD 2018-01-01 – 2018-12-31: -12687000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2018-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -12687000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12687000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459021012523/achv-20201231.xml#283484 Filing: 000156459021012523 The citation records this snapshot. The page link may show a newer release later.	−USD 10.62 million Exact value Exact value: -10623000 USD 2018-01-01 – 2018-12-31: -10623000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2018-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -10623000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10623000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459021012523/achv-20201231.xml#326148 Filing: 000156459021012523 The citation records this snapshot. The page link may show a newer release later.	USD 46,000 Exact value Exact value: 46000 USD 2018-01-01 – 2018-12-31: 46000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2018-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 46000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 46000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459021012523/achv-20201231.xml#331096 Filing: 000156459021012523 The citation records this snapshot. The page link may show a newer release later.	−USD 10.67 million Calculation and evidence -10623000 − 46000 USD Exact free cash flow: -10669000 USD 2018-01-01 – 2018-12-31: -10623000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 46000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2018-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -10669000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10623000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459021012523/achv-20201231.xml#326148 Filing: 000156459021012523 Input fundies:CapitalExpenditure: 46000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459021012523/achv-20201231.xml#331096 Filing: 000156459021012523 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 16.4 million Exact value Exact value: -16395000 USD 2019-01-01 – 2019-12-31: -16395000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2019-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -16395000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16395000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm#3280269 Filing: 000156459022009485 The citation records this snapshot. The page link may show a newer release later.	−USD 15.22 million Exact value Exact value: -15216000 USD 2019-01-01 – 2019-12-31: -15216000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2019-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -15216000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15216000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm#2072947 Filing: 000156459022009485 The citation records this snapshot. The page link may show a newer release later.	USD 53,000 Exact value Exact value: 53000 USD 2019-01-01 – 2019-12-31: 53000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2019-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 53000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 53000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm#2154775 Filing: 000156459022009485 The citation records this snapshot. The page link may show a newer release later.	−USD 15.27 million Calculation and evidence -15216000 − 53000 USD Exact free cash flow: -15269000 USD 2019-01-01 – 2019-12-31: -15216000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 53000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2019-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -15269000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15216000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm#2072947 Filing: 000156459022009485 Input fundies:CapitalExpenditure: 53000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm#2154775 Filing: 000156459022009485 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 14.73 million Exact value Exact value: -14730000 USD 2020-01-01 – 2020-12-31: -14730000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2020-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -14730000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14730000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-10k_20221231.htm#3261005 Filing: 000156459023003800 The citation records this snapshot. The page link may show a newer release later.	−USD 13.47 million Exact value Exact value: -13474000 USD 2020-01-01 – 2020-12-31: -13474000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2020-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -13474000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13474000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-10k_20221231.htm#2025106 Filing: 000156459023003800 The citation records this snapshot. The page link may show a newer release later.	USD 17,000 Exact value Exact value: 17000 USD 2020-01-01 – 2020-12-31: 17000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2020-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 17000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-10k_20221231.htm#2123015 Filing: 000156459023003800 The citation records this snapshot. The page link may show a newer release later.	−USD 13.49 million Calculation and evidence -13474000 − 17000 USD Exact free cash flow: -13491000 USD 2020-01-01 – 2020-12-31: -13474000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 17000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2020-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -13491000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13474000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-10k_20221231.htm#2025106 Filing: 000156459023003800 Input fundies:CapitalExpenditure: 17000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-10k_20221231.htm#2123015 Filing: 000156459023003800 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 33.15 million Exact value Exact value: -33152000 USD 2021-01-01 – 2021-12-31: -33152000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2021-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -33152000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33152000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000095017024038049/achv-20231231.htm#2452616 Filing: 000095017024038049 The citation records this snapshot. The page link may show a newer release later.	−USD 29.44 million Exact value Exact value: -29440000 USD 2021-01-01 – 2021-12-31: -29440000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2021-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -29440000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29440000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000095017024038049/achv-20231231.htm#1460304 Filing: 000095017024038049 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 42.35 million Exact value Exact value: -42350000 USD 2022-01-01 – 2022-12-31: -42350000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2022-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -42350000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42350000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/achv-20241231.htm#3132919 Filing: 000095017025036831 The citation records this snapshot. The page link may show a newer release later.	−USD 37.57 million Exact value Exact value: -37569000 USD 2022-01-01 – 2022-12-31: -37569000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2022-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -37569000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37569000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/achv-20241231.htm#1783287 Filing: 000095017025036831 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 29.82 million Exact value Exact value: -29815000 USD 2023-01-01 – 2023-12-31: -29815000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2023-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -29815000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29815000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#3537825 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	−USD 24.48 million Exact value Exact value: -24479000 USD 2023-01-01 – 2023-12-31: -24479000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2023-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -24479000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24479000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1877077 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2023-01-01 – 2023-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2023-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1952969 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	−USD 24.5 million Calculation and evidence -24479000 − 21000 USD Exact free cash flow: -24500000 USD 2023-01-01 – 2023-12-31: -24479000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2023-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -24500000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24479000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1877077 Filing: 000119312526120690 Input fundies:CapitalExpenditure: 21000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1952969 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 39.83 million Exact value Exact value: -39827000 USD 2024-01-01 – 2024-12-31: -39827000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2024-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -39827000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39827000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#3536102 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	−USD 29.77 million Exact value Exact value: -29770000 USD 2024-01-01 – 2024-12-31: -29770000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2024-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -29770000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29770000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1875301 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 54.65 million Exact value Exact value: -54648000 USD 2025-01-01 – 2025-12-31: -54648000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Net Income: -54648000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54648000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#3534379 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	−USD 49.5 million Exact value Exact value: -49500000 USD 2025-01-01 – 2025-12-31: -49500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Operating Cash Flow: -49500000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49500000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#2013479 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	USD 3,000 Exact value Exact value: 3000 USD 2025-01-01 – 2025-12-31: 3000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Capital Expenditure: 3000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1949831 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.	−USD 49.5 million Calculation and evidence -49500000 − 3000 USD Exact free cash flow: -49503000 USD 2025-01-01 – 2025-12-31: -49500000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 3000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ONCOGENEX PHARMACEUTICALS, INC. · 2025-12-31 ONCOGENEX PHARMACEUTICALS, INC. (edgar:949858) Free cash flow: -49503000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:06:13Z Snapshot: 5359d5cd6c038c3562554f5dc97797b9993f51638db45612874ff349b00c46f7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/949858?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49500000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#2013479 Filing: 000119312526120690 Input fundies:CapitalExpenditure: 3000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#1949831 Filing: 000119312526120690 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

151 filings · 3,319 latest values · 3,319 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000949858, 949858, ACHV, OGXI, edgar:949858

Also known as ACHIEVE LIFE SCIENCES, INC., Achieve Life Sciences, Inc., ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC

ONCOGENEX PHARMACEUTICALS, INC.

Latest fiscal year

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation